{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:07:51Z","timestamp":1788541671440,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.clml.2022.10.001","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T04:40:41Z","timestamp":1665463241000},"page":"68-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed\/Refractory Multiple Myeloma in the CARTITUDE-1 Study"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-3843","authenticated-orcid":false,"given":"Adam D.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Hari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myo","family":"Htut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-0376","authenticated-orcid":false,"given":"Jesus G.","family":"Berdeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepu","family":"Madduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsi","family":"Olyslager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna D.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Schecter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn C.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine S.","family":"Gries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Fastenau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Valluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Deraedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Akram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0489-7754","authenticated-orcid":false,"given":"Rebecca","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Doward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silene ten","family":"Seldam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Jakubowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.10.001_bib0001","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","article-title":"Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update","volume":"78","author":"Nijhof","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.clml.2022.10.001_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","article-title":"Treatment Options for Triple-class Refractory Multiple Myeloma","volume":"20","author":"Mikhael","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.10.001_bib0003","first-page":"e528","article-title":"Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2022.10.001_bib0004","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.clml.2019.10.002","article-title":"Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry","volume":"20","author":"Jagannath","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.10.001_bib0005","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.10.001_bib0006","first-page":"2789","article-title":"Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life","volume":"23","author":"Baz","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2022.10.001_bib0007","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12885-019-5467-x","article-title":"Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study","volume":"19","author":"Parsons","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2022.10.001_bib0008","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1080\/10428194.2020.1747066","article-title":"Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma","volume":"61","author":"Weisel","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.10.001_bib0009","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/j.clml.2020.10.002","article-title":"Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany","volume":"21","author":"Engelhardt","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.10.001_bib0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbmt.2008.09.023","article-title":"Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation","volume":"15","author":"Sherman","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2022.10.001_bib0011","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s11136-019-02392-6","article-title":"How are patient-reported outcomes and symptoms being measured in adults with relapsed\/refractory multiple myeloma? A systematic review","volume":"29","author":"LeBlanc","year":"2020","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clml.2022.10.001_bib0012","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/014107680009301205","article-title":"Expectations and quality of life of cancer patients undergoing radiotherapy","volume":"93","author":"Koller","year":"2000","journal-title":"Journal of the Royal Society of medicine"},{"key":"10.1016\/j.clml.2022.10.001_bib0013","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","article-title":"Health related quality of life in a nationally representative sample of haematological patients","volume":"83","author":"Johnsen","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.10.001_bib0014","unstructured":"CARVYKTI (ciltacabtagene autoleucel) Highlights of Prescribing Information. 2022."},{"key":"10.1016\/j.clml.2022.10.001_bib0015","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2 years post LPI","author":"Martin","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clml.2022.10.001_bib0016","first-page":"0","article-title":"Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\u20132, open-label study","author":"Martin","year":"2022","journal-title":"Lancet Haematology"},{"key":"10.1016\/j.clml.2022.10.001_bib0017","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.10.001_bib0018","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.clml.2022.10.001_bib0019","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/ejh.12790","article-title":"Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis","volume":"97","author":"Ramsenthaler","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.10.001_bib0020","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/17474086.2019.1613886","article-title":"Quality of life in multiple myeloma: considerations and recommendations","volume":"12","author":"Seitzler","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2022.10.001_bib0021","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/ejh.12012","article-title":"What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools","volume":"89","author":"Osborne","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.10.001_bib0022","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjh.15248","article-title":"Patient-reported outcomes of multiple myeloma patients treated with panobinostat after >\/=2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial","volume":"181","author":"Richardson","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.10.001_bib0023","first-page":"e1603","article-title":"The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies","author":"Crawford","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.clml.2022.10.001_bib0024","doi-asserted-by":"crossref","first-page":"8030","DOI":"10.1200\/JCO.2022.40.16_suppl.8030","article-title":"Health-related quality of life (HRQoL) in patients with relapsed\/refractory multiple myeloma (RRMM) receiving real-life current standard of care (SOC) in the LocoMMotion study","volume":"40","author":"Delforge","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clml.2022.10.001_bib0025","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1007\/s00415-020-10237-3","article-title":"Neurological updates: neurological complications of CAR-T therapy","volume":"268","author":"Tallantyre","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.clml.2022.10.001_bib0026","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022016925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022016925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:14Z","timestamp":1761871274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022016925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2152265022016925"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.10.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed\/Refractory Multiple Myeloma in the CARTITUDE-1 Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}